Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Anemia

Therapeutic area intelligence for Anemia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Astellas Pharma →

Assets

Erythropoietin →

Recent signals(2)

ClinicalJuly 31, 2026

Study on Erythropoietin's Impact on Hepcidin Levels in Healthy Volunteers

This study aims to assess how intravenous erythropoietin affects serum and urinary hepcidin levels.

ClinicalJuly 27, 2026

Roxadustat Study for Anemia in Children with Chronic Kidney Disease Initiated by Astellas Pharma

Astellas Pharma is conducting a study to evaluate the efficacy of roxadustat in treating anemia in children and teenagers with chronic kidney disease, with a duration of up to 52 weeks.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.